Kohima News Paper

Glaucoma Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

 Breaking News
  • No posts were found

Glaucoma Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

September 26
23:40 2022
Glaucoma Market  Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Glaucoma Market
DelveInsight’s ‘Glaucoma Market Insights, Epidemiology, and Market Forecast 2032’ report deliver an in-depth understanding of the Glaucoma, historical and forecasted epidemiology as well as the Glaucoma market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

DelveInsight’s Glaucoma Market Insights, Epidemiology, and Market Forecast 2032’ report deliver an in-depth understanding of the Glaucoma, historical and forecasted epidemiology as well as the Glaucoma market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

The Glaucoma market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Glaucoma market size from 2019 to 2032. The Report also covers current Glaucoma treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Some of the key facts of the Glaucoma  Market Report:

  • Japan had 2,903,850 diagnosed prevalent cases for Glaucoma in 2021.
  • Among the European five countries, Germany had the highest diagnosed prevalent population of Glaucoma with  1,042,657 cases, followed by Italy and France in 2021. On the other hand, Spain had the lowest number of diagnosed cases. 
  • Among the major types of Glaucoma, i.e., open-angle and closed-angle glaucoma, the former one accounts for a higher number of diagnosed Glaucoma cases.

 

Key Benefits of the Glaucoma Market report:

  • The report covers the descriptive overview of Glaucoma, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into Glaucoma epidemiology and treatment
  •  Additionally, an all-inclusive account of both the current and emerging therapies for Glaucoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Glaucoma market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Glaucoma market.

Got queries? Click here to know more about the Glaucoma Market Landscape

Glaucoma Overview

Glaucoma is a disease that damages the eye’s optic nerve. It usually happens when fluid builds up in the front part of the eye. That extra fluid increases the pressure in eye, damaging the optic nerve. The condition is a leading cause of blindness for people over 60 years old. But blindness from glaucoma can often be prevented with early treatment. There are two main types of glaucoma – primary and secondary.

 

The difference between primary and secondary glaucoma is that secondary glaucoma is caused by external reasons. An injury to the eye, inflammation in the eye, diabetes, or the use of steroids can lead to an increase of intraocular pressure. As in primary glaucoma, increased eye pressure can damage the optic nerve and cause vision loss. This type of glaucoma is usually detected while treating the underlying cause.There are two major types of glaucoma, i.e., Primary open-angle glaucoma (POAG), and Angle-closure /glaucoma closed-angle glaucoma/narrow-angle glaucoma. The “angle” in both cases refers to the drainage angle inside the eye that controls the outflow of the watery fluid (aqueous) which is being produced inside the eye.Primary open-angle glaucoma is the most common type of glaucoma that happens gradually, where the eye does not drain fluid as well as it should (like a clogged drain). Whereas, angle-closure glaucoma happens when someone’s iris is very close to the drainage angle in their eye.

 

 

Glaucoma Epidemiological Insights:

 

  1. The total diagnosed prevalent population of Glaucoma in the 7MM was estimated to be 10,201,786 cases in 2021, which is expected to increase in the forecast period (2022-2032). 
  2. Total type-specific diagnosed prevalence of OAG for Primary and Secondary in the US was assessed to be 2,643,800 and 293,756 in 2021.

Glaucoma Market  Epidemiological Segmentation 

  • Type-specific (Open/Closed) Diagnosed Prevalent Population of Glaucoma 
  • Age-specific Diagnosed Prevalence of Glaucoma 
  • Type-specific (Primary/Secondary) Diagnosed Prevalence of Open-Angle Glaucoma
  •  Gender-specific Diagnosed Prevalence of Glaucoma 

Glaucoma Market Outlook 

Glaucoma is an eye disease that gradually steals vision. There are typically no early warning signs or painful symptoms of glaucoma. It develops slowly and sometimes without noticeable sight loss for many years.

 

The damage caused by glaucoma cannot be reversed. But treatment and regular checkups can help slow or prevent vision loss, especially if the disease is in its early stages. Glaucoma is treated by lowering the eye pressure (intraocular pressure). Depending on the situation, the options may include prescription eye drops, oral medications, laser treatment, surgery or a combination of any of these.

 

Management of the disease focuses on lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. However, these treatments have not helped all patients. Some patients continue to experience deterioration in the optic nerve even though their IOPs are within the normal range. Besides these pharmacological treatment measurements, incisional surgery, laser surgery, and medication are also preferred.

 

There are several risk factors like age > 60 years, genetic predisposition, certain eye characteristics (such as a pupillary defect, thin cornea, and myopia), low educational status, smoking, African descent, and visual problems are associated with this indication and treatment pattern varies accordingly.

 

Learn more by requesting for sample @ Glaucoma Market Landscape

Glaucoma Key Companies  

  • Laboratori
  • Santen Pharmaceutical
  • SPARC
  • And others

 

Glaucoma Therapies 

  • PDP-716
  • PRO-122
  • EYELIS/Omidenepag isopropyl/DE-117
  • DE-130A
  • Sepetaprost (DE-126/ONO-9054)
  • And others

Table of Contents

  •  Key Insights 
  •  Report Introduction 
  •  Executive Summary of Glaucoma
  •  Disease Background and Overview
  •  Epidemiology and patient population
  •  The United States 
  •  EU 5
  •  Glaucoma  Emerging Therapies
  •  Glaucoma  Market Outlook
  •  Market Access and Reimbursement of Therapies
  •  Appendix
  •  Glaucoma  Report Methodology
  •  DelveInsight Capabilities
  •  Disclaimer
  •  About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/